Literature DB >> 27076411

Group sequential designs with prospectively planned rules for subpopulation enrichment.

Michael Rosenblum1, Brandon Luber2, Richard E Thompson1, Daniel Hanley2.   

Abstract

We propose a class of randomized trial designs aimed at gaining the advantages of wider generalizability and faster recruitment while mitigating the risks of including a population for which there is greater a priori uncertainty. We focus on testing null hypotheses for the overall population and a predefined subpopulation. Our designs have preplanned rules for modifying enrollment criteria based on data accrued at interim analyses. For example, enrollment can be restricted if the participants from a predefined subpopulation are not benefiting from the new treatment. Our designs have the following features: the multiple testing procedure fully leverages the correlation among statistics for different populations; the asymptotic familywise Type I error rate is strongly controlled; for outcomes that are binary or normally distributed, the decision rule and multiple testing procedure are functions of the data only through minimal sufficient statistics. Our designs incorporate standard group sequential boundaries for each population of interest; this may be helpful in communicating the designs, because many clinical investigators are familiar with such boundaries, which can be summarized succinctly in a single table or graph. We demonstrate these designs through simulations of a Phase III trial of a new treatment for stroke. User-friendly, free software implementing these designs is described.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adaptive enrichment design; group sequential design; optimal sample size

Mesh:

Year:  2016        PMID: 27076411     DOI: 10.1002/sim.6957

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.

Authors:  Thomas A Murray; Ying Yuan; Peter F Thall; Joan H Elizondo; Wayne L Hofstetter
Journal:  Biometrics       Date:  2018-01-22       Impact factor: 2.571

Review 2.  Challenges and opportunities in biomarker-driven trials: adaptive randomization.

Authors:  Yeonhee Park
Journal:  Ann Transl Med       Date:  2022-09

3.  Designing and analyzing clinical trials for personalized medicine via Bayesian models.

Authors:  Chuanwu Zhang; Matthew S Mayo; Jo A Wick; Byron J Gajewski
Journal:  Pharm Stat       Date:  2021-01-19       Impact factor: 1.894

4.  Stochastic optimization of adaptive enrichment designs for two subpopulations.

Authors:  Aaron Fisher; Michael Rosenblum
Journal:  J Biopharm Stat       Date:  2018-08-10       Impact factor: 1.503

5.  Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.

Authors:  Yeonhee Park; Suyu Liu; Peter F Thall; Ying Yuan
Journal:  Biometrics       Date:  2021-01-27       Impact factor: 1.701

6.  Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.

Authors:  Alex G Karanevich; Jeffrey M Statland; Byron J Gajewski; Jianghua He
Journal:  BMC Med Res Methodol       Date:  2018-02-06       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.